Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

96 Tschan Mario P. | KFS 02486082009 | CHF 262,500.– Medizinische Onkologie/Hämatologie, Departement für klinische Forschung, Universität Bern, Bern The importance of autophagy in normal and leukemic myelopoiesis Weller Michael | KFS 02694082010 | CHF 195,700.– Klinik für Neurologie, UniversitätsSpital Zürich, Zürich Angiogenesis and invasion in glioblastoma: The therapeutic options and risks of co-targeting VEGF and TGF-beta Widmann Christian | KFS 02543022010 | CHF 205,300.– Département de physiologie, Faculté de biologie et de médecine, Université de Lausanne, Lausanne The 317-326 sequence of RasGAP as potential anti-metastatic agent Wymann Matthias Paul | KFS 02680082010 | CHF 343,000.– Institut für Biochemie und Genetik, Departement Biomedizin, Universität Basel, Basel Identification and modulation of targets to reprogram glioblastoma cancer stem cells Zaugg Kathrin | KLS 02569022010 | CHF 78,000.– Labor für angewandte RadioOnkologie, UniversitätsSpital Zürich, Zürich Elucidating the role of the hypoxia-protective gene CPT1C (Carnitine Palmitoyl-transferase 1C) in carcinogenesis Zavolan Mihaela | KFS 02477082009 | CHF 303,000.– Departement Biozentrum, Universität Basel, Basel Identification of cancer-related targets of individual members of the miR-17~92 cluster of miRNAs Approved bursaries in 2009/2010 Total funds allocated: CHF 722,132.– Cornaz Sandrine | MDPhD 02607062010 | CHF 180,533.– Mechanisms that regulate primary cell genetic reprogramming and differentiation by sarcoma-associated fusion genes (SAMW MD-PhD bursary) Zielort: Institut de pathologie, Centre hospitalier universitaire vaudois (CHUV), Lausanne Ecsedi Matyas | MDPhD 02431062009 | CHF 180,533.– Regulation of the let-7 tumor suppressor microRNA in development and cancer (SAMW MD-PhD bursary) Zielort: Labor Grosshans, Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel Essig Martin | MDPhD 02606062010 | CHF 180,533.– Transition from paediatric to adult care for childhood cancer survivors (SAMW MD-PhD bursary) Zielort: Forschungsgruppe Kinder und Jugendlichengesundheit, Institut für Sozial und Präventivmedizin (ISPM), Universität Bern, Bern Özdemir Berna | MDPhD 02430062009 | CHF 180,533.– Tumour-stroma interactions in prostate cancer bone metastasis (SAMW MD-PhD bursary) Zielort: Forschungsgruppe Urologie, Departement für klinische Forschung, Universität Bern, Bern
Basic biomedical research Presentation of approved research projects in 2009/2010 Aguet Michel | Role of BCL9/BCL9L in regulating Wnt-mediated epithelial-mesenchymal transition, stem cell traits and drug sensitivity in Wnt-activated human cancers (KFS 02674082010) Duration: 01.09.2010 – 01.09.2012 A major problem of anticancer therapies is tumour relapse, typically associated with resistance to therapy. Recent observations suggest that tumour cells with stem celllike properties, including notably reduced susceptibility to common chemotherapeutic agents, are often at the origin of relapses. Our group recently reported that in a mouse model of colon cancer, inactivation of BCL9 proteins suppresses malignancy traits, including stem cell markers. Our current studies focus on validating the relevance of these observations for human colon cancer. Specifically, we will address to what extent inhibition of BCL9 results in attenuated stem cell properties and, most importantly, whether susceptibility to therapy might thereby get enhanced. The project should therefore contribute to establishing BCL9 proteins as targets for a novel therapy aimed at restoring responsiveness to therapy, and to justifying the search for small compound BCL9 inhibitors. Project coordinator Prof. Dr Michel Aguet Institut suisse de recherche expérimentale sur le cancer (ISREC) NCCR Molecular Oncology Faculté sciences de la vie EPF de Lausanne (EPFL) c/o Département de pathologie Rue du Bugnon 25 CH1011 Lausanne Phone +41 (0)21 314 72 17 michel.aguet@epfl.ch Basler Konrad | Characterization of the role of histone binding by the WnT signaling components Pygo2 in murine models of breast cancer and colon cancer (KFS 02443082009) Duration: 01.01.2010 – 01.01.2013 Colon and breast cancer are two of the most common types of tumours. Dysregulation of the Wnt signalling cascade is known to underlie their formation. The goal of this project is to better understand the role played by Pygopus, a key component of the Wnt signalling pathway. It is now well accepted that “decoding” the marks found on histones is an essential part of the process that determines if expression of a gene is turned on or off. Histones are the proteins that together with DNA form chromatin – the basis of our genome. We want to find out if Pygopus can act as a histone code reader and in this way contributes to the activation of the genetic program triggered by the Wnt signal. The insights gained from this study will provide important insights into how the Wnt signalling cascade contributes to colon and breast cancer progression and will open new avenues for the treatment of these cancers. Project coordinator Prof. Dr. Konrad Basler Institut für molekulare Biologie Universität Zürich Winterthurerstrasse 190 CH8057 Zürich Phone +41 (0)44 635 31 10 basler@molbio.uzh.ch Becher Burkhard | Cellular and molecular characterization of IL-12-mediated tumor suppression (KFS 02441082009) Duration: 01.05.2010 – 01.05.2012 Immune cells (white blood cells) and their secreted signalling molecules play a critical role in tumour control and elimination. In a variety of tumour models, the signalling molecule interleukin12 (IL12) has been shown to repress tumour growth. Yet, IL12 injection into the blood of human patients led to severe adverse effects, and therefore the development of IL12 therapies has been halted. To this day, the molecular and cellular events of IL12 have been illunderstood. By defining the mechanistic underpinnings of how IL12 works, we shed light on how tumour cells and immune cells interact in general, and in particular we will enhance the therapeutic targeting of malignancies in humans. The tumouricidal activity of IL12 was widely held to be mediated by two specific subsets of white blood cells, the natural killer cells and the T lymphocytes. However, we found that tumour suppression is mediated independently of these two subsets. Instead, we were able to demonstrate that IL12 initiates powerful local antitumour immunity by stimulating a subset of lymphoid tissue inducer (LTi) cells. These cells seem to alter the blood vessels within the tumour mass in a way that allows immune cells to enter the tumour and actively fight it. Lastly, our findings also demonstrate that IL12 should be injected directly into the tumour, thereby limiting the adverse effects observed after injection into the blood stream. Project coordinator Prof. Dr. Burkhard Becher Institut für experimentelle Immunologie Universität Zürich Y44J92 (Office), J38/42 (Lab) Winterthurerstrasse 190 CH8057 Zürich Phone +41 (0)44 635 37 03 Fax +41 (0)44 635 68 83 burkhard.becher@neuroimm.uzh.ch 97
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12:
gramme research funding decreased b
Page 13 and 14:
Table 2 Distribution of funds for i
Page 15 and 16:
Funding patient-centred research Pa
Page 17 and 18:
value was not clearly discernible.
Page 19 and 20:
New organization of the Foundation
Page 21 and 22:
The board of the Foundation Cancer
Page 23 and 24:
The president of the Scientific Com
Page 25 and 26:
Prof. Martin Pruschy, PhD Departmen
Page 27 and 28:
Swartz wants to find out how tumour
Page 29 and 30:
The scientific and medical research
Page 31 and 32:
3. The original order/sequence of t
Page 33 and 34:
As a federation, the Cancer League
Page 35 and 36:
List of funded research projects, i
Page 37 and 38:
Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40:
Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42:
Thurgau Cancer League Biotechnologi
Page 43 and 44:
Weller Michael | 2010: CHF 65,828.-
Page 45 and 46:
manageable funding of individual pr
Page 47 and 48: enhances breast cancer cell motilit
Page 49 and 50: Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52: International Clinical Cancer Resea
Page 53 and 54: in PHIV were shown for Hodgkin’s
Page 55: Zucca Emanuele et al. | Internation
Page 58 and 59: 56 “hierarchical structure” of
Page 60 and 61: 58 the attempt should be made to st
Page 62 and 63: 60 Gönczy Pierre | KLS 0202402
Page 64 and 65: 62 Romero Pedro | OCS 020110220
Page 66 and 67: 64 Beermann Friedrich | In vivo scr
Page 68 and 69: 66 Christofori Gerhard | Podoplanin
Page 70 and 71: 68 Frei Christian | The function of
Page 72 and 73: 70 cell, this novel mechanism serve
Page 74 and 75: 72 Results The induction of viral p
Page 76 and 77: 74 Hübscher Ulrich | Repair of oxi
Page 78 and 79: 76 Methods and experimental approac
Page 80 and 81: 78 of cMyc and/or NMyc and demo
Page 82 and 83: 80 In summary, this work improves o
Page 84 and 85: 82 Pruschy Martin | Microtubule int
Page 86 and 87: 84 Renner Christoph | Selective inh
Page 88 and 89: 86 Goal Here we build on these obse
Page 90 and 91: 88 by TDG prevents efficient downst
Page 92 and 93: 90 To address these questions, we a
Page 94 and 95: 92 Translational relevance The resu
Page 96 and 97: 94 Grünberg Jürgen | KFS 025460
Page 100 and 101: 98 Boyman Onur | Preclinical testin
Page 102 and 103: 100 Constam Daniel | Role of activi
Page 104 and 105: 102 this study we will examine the
Page 106 and 107: 104 Janscak Pavel | Study of the ro
Page 108 and 109: 106 Müller Anne | The molecular pa
Page 110 and 111: 108 Radtke Freddy | The role of Not
Page 112 and 113: 110 Schär Primo | DNA repair, epig
Page 114 and 115: 112 In this project we will investi
Page 116 and 117: 114
Page 118 and 119: 116 and Research). Other financial
Page 120 and 121: 118 be totally unaffordable for aca
Page 122 and 123: 120 Clinical research List of compl
Page 124 and 125: 122 Hunger Robert E. | OCS 02262-08
Page 126 and 127: 124 Clinical research Presentation
Page 128 and 129: 126 Benhattar Jean | Identification
Page 130 and 131: 128 Bertoni Francesco | Genome-wide
Page 132 and 133: 130 Interpretation ESA treatment in
Page 134 and 135: 132 Our results could pave the way
Page 136 and 137: 134 new drugs that specifically tar
Page 138 and 139: 136 slides in two different concent
Page 140 and 141: 138 Conclusions A strong network of
Page 142 and 143: 140 tions introduced to ARE motifs
Page 144 and 145: 142 Müller Beatrice U. | The maste
Page 146 and 147: 144 A novel method was developed fo
Page 148 and 149:
146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151:
148 Timmermann Beate | Prospective
Page 152 and 153:
150 recurrence of the disease, we a
Page 154 and 155:
152 Zucca Emanuele | A prospective
Page 156 and 157:
154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159:
156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161:
158 activity at the single cell lev
Page 162 and 163:
160 Our research projects aim at un
Page 164 and 165:
162 Körner Meike | In vitro evalua
Page 166 and 167:
164 Nadal David | Is endemic Burkit
Page 168 and 169:
166 (> 50.000/patient). For their a
Page 170 and 171:
168 Zeller Rolf | Functional analys
Page 172 and 173:
170
Page 174 and 175:
172 area of health services researc
Page 176 and 177:
174 The financing of palliative car
Page 178 and 179:
176 National Strategy for Palliativ
Page 180 and 181:
178 Psychosocial research List of c
Page 182 and 183:
180 Within the patient group, level
Page 184 and 185:
182 Further, the results suggest th
Page 186 and 187:
184 It is in this context that the
Page 188 and 189:
186 Recommendation Female spouses o
Page 190 and 191:
188 Psychosocial research Presentat
Page 192 and 193:
190 rates communication skills rema
Page 195 and 196:
Epidemiological research Epidemiolo
Page 197 and 198:
data from cancer registries. In the
Page 199 and 200:
The importance of cancer registries
Page 201 and 202:
Ess Silvia | Patterns of care and s
Page 203 and 204:
Epidemiological research List of ap
Page 205 and 206:
Impact This work will serve as the
Page 207 and 208:
Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

Create successful ePaper yourself

Delete template?

Save as template?